ReviewACS pharmacology & translational science2026
Recommended Tool Compounds: Isoform- and Class-Specific Histone Deacetylase Inhibitors.
Review in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Discovery of a Selective Histone Deacetylase 6 Degrader (HDAC6 PROTAC) with a Short and Rigid Linker Demonstrating Sustained Knockdown of HDAC6ACS medicinal chemistry letters · 2026Article
- Cellular Target Engagement and Dissociation Kinetics of Class I-Selective Histone Deacetylase (HDAC) Inhibitors.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of selective histone deacetylase inhibitors (HDACi) and thus the identification of suitable chemical probes is still highly complex. Moreover, in the past, the results of oversimplified biochemical HDAC assays have often been overinterpreted. This has led to the extensive use of various supposedly isoform-selective HDACi as chemical probes to investigate the biological function of specific HDAC isoforms and classes. Considering more recent insights concerning the structure, binding kinetics, as well as substrate specificity of several HDAC isoforms, at least some of these studies should be reevaluated thoroughly. In this review, we present a selection of possible tool compounds for use in biological and pharmacological studies to investigate the biological function of specific HDAC isoforms or classes and comprehensively discuss their limitations based on the currently available data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.